A clinical trial with IDIBELL participation confirms the benefits of a new drug in heart failure
Dapagliflozin significantly reduces the risk of cardiovascular death and hospitalizations for heart failure (HF).
Dapagliflozin significantly reduces the risk of cardiovascular death and hospitalizations for heart failure (HF).
It is an epigenetic test capable of detecting between 90 and 100% of cases of endometrial cancer. This new rapid and non-invasive method can be performed: on cervical cytology samples obtained in the doctor’s office, and on vaginal self-samples collected at home.
A new endometrial cancer screening test that can be done at home Read More »
A retrospective study by IDIBELL and the Bellvitge University Hospital shows that starting physical rehabilitation of patients admitted to the UCRI with severe COVID-19 before seven days reduces hospitalization time.
Early physical therapy in patients with severe COVID-19 can reduce hospitalization days Read More »
The research, led by researchers from IDIBELL and the Bellvitge University Hospital (HUB), has established that when amyloidosis is detected in the prostate, it is almost always the TTR-type systemic variant of the disease associated with aging.
Among recent achievements, first of all, the entry into force of the WHO Framework Convention on Tobacco Control in 2005 stands out, which has surely been the most important milestone, not only for tobacco control, but as a paradigm of public health on a global scale.
Tobacco control in the 21st century: A global and local perspective Read More »
The Aula L’H program on L’Hospitalet digital television, specialized in education, together with the Institut Bellvitge and IDIBELL, have carried out, throughout the 2021-22 academic year, a complete edition of the Women of Science section, entirely dedicated to disseminating the research work, the research career and the personality of five IDIBELL scientists.
Twenty-nine reference centers from the United States, Canada, the Netherlands, Italy, France, and Spain, including IDIBELL, have participated in an international multicenter study that validated a model for predicting the risk of ventricular arrhythmias and sudden death in arrhythmogenic cardiomyopathy of the right ventricle (ARVC).
Validated a tool that assesses the risk of sudden death due to a heart disease Read More »
The drug inhibits the S6K1 protein, which is essential for the development of new fat cells, responsible for the disproportionate growth of fat deposits in obese people.